---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-000693"
form_type: "8-K"
ticker: "LPCN"
cik: "0001535955"
company_name: "Lipocine Inc."
filed_at: "2025-03-26T23:59:59+00:00"
generated_at: "2026-05-24T04:56:41.881724+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Lipocine initiates Phase 3 outpatient PPD trial of LPCN 1154; dosing expected Q2 2025

## Summary
- Initiation of randomized, blinded, placebo-controlled Phase 3 trial of LPCN 1154 for PPD; first patient dosing expected Q2 2025.
- 48-hour at-home self-administration regimen based on FDA protocol feedback.
- Primary endpoint: change from baseline in HAM-D; secondary endpoints include MADRS and HAM-A.
- Trial size powered based on observed effect of injectable brexanolone (Zulresso).

## SEC filing metadata
- accession: 0001641172-25-000693
- form_type: 8-K
- ticker: LPCN
- cik: 0001535955
- company_name: Lipocine Inc.
- filed_at: 2025-03-26T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1535955/000164117225000693/0001641172-25-000693-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1535955/000164117225000693/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-000693
- JSON: https://secwatch.observer/filing/0001641172-25-000693.json
- Plain text: https://secwatch.observer/filing/0001641172-25-000693.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.